


USSN: 09/907,515

CLAIMS

Please amend claims 24, 47, and 51 as set forth below:

## Claims 1-23 (Cancelled)

**24. (Currently Amended)** A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR7, -SR7, a halogen or -N(R9)R10;

R9 and R10, each independently, represent -H, alkyl, alkenyl, -(CH2)n-R7, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R7 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle; and

wherein the ligand V comprises-a heterocycle, optionally aromatic and optionally substituted, that comprises W and Y and has from 4 to about 8 atoms in the ring structure.

and wherein the symbol  represents a single or a double bond.

**25. (Original)** The coordination complex of claim 24, wherein W is N.

**26. (Original)** The coordination complex of claim 24, wherein Pt is Pt(II).

**27. (Original)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 24 and a pharmaceutically acceptable carrier.

USSN: 09/907,515

28. (Original) The pharmaceutical composition of claim 27, wherein said coordination complex is ammine(2-amino-3-picoline)dichloroplatinum(II).

Claims 29-32 (Cancelled)

33. (Previously Presented) The coordination complex of claim 24, wherein V is a 6-membered aromatic heterocycle.

34. (Previously Presented) The coordination complex of claim 33, wherein V is pyridine or a substituted pyridine.

35. (Previously Presented) The coordination complex of claim 33, wherein V is picoline or a substituted picoline.

36. (Previously Presented) The coordination complex of claim 24, wherein Pt is Pt(IV) and two additional ligands in the trans axial positions are present.

37. (Previously Presented) The coordination complex of claim 36, wherein said each of said additional ligands comprise a carboxylate group.

38. (Previously Presented) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 36 and a pharmaceutically acceptable carrier.

39. (Previously Presented) The pharmaceutical composition of claim 38, wherein said coordination complex is ammine(2-amino-3-picoline)dichlorodiacetoplatinum(IV).

40. (Previously Presented) The coordination complex of claim 24, wherein both X are halogens.

41. (Previously Presented) The coordination complex of claim 40, wherein said halogen is chlorine.

42. (Previously Presented) The coordination complex of claim 24, wherein both X comprise a carboxylate group.

43. (Previously Presented) The coordination complex of claim 42, wherein said carboxylate group is a chelating dicarboxylate.


USSN: 09/907,515

**44. (Previously Presented)** The coordination complex of claim 42, wherein at least one X is acetate.

**45. (Previously Presented)** The coordination complex of claim 24, wherein L is an amine having the structure NR<sub>2</sub>(R<sub>3</sub>), wherein R<sub>2</sub> and R<sub>3</sub> each independently represent a hydrogen, an alkyl, an alkenyl, -(CH<sub>2</sub>)<sub>m</sub>-R<sub>4</sub>, or R<sub>2</sub> and R<sub>3</sub>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; and wherein R<sub>2</sub> represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.

**46. (Previously Presented)** The coordination complex of claim 24, wherein L is an ammine.

**47. (Currently Amended)** A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR<sub>7</sub>, -SR<sub>7</sub>, a halogen or -N(R<sub>9</sub>)R<sub>10</sub>;

R<sub>9</sub> and R<sub>10</sub>, each independently, represent -H, alkyl, alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-R<sub>7</sub>, or R<sub>9</sub> and R<sub>10</sub>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R<sub>7</sub> represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle; and

wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises W and Y and has from 4 to about 8 atoms in the ring structure;

USSN: 09/907,515


and wherein the symbol  represents a single or a double bond.

**48. (Previously Presented)** The coordination complex of claim 47, wherein each of X is a halogen.

**49. (Previously Presented)** The coordination complex of claim 48, wherein said halogen is chlorine.

**50. (Previously Presented)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 47 and a pharmaceutically acceptable carrier.

**51. (Currently Amended)** A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR7, -SR7, a halogen or -N(R9)R10;

R9 and R10, each independently, represent -H, alkyl, alkenyl, -(CH2)n-R7, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R7 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle; and

wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises W and Y and has from 4 to about 8 atoms in the ring structure;.

USSN: 09/907,515

and wherein the symbol  represents a single or a double bond.

52. (Previously Presented) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 51 and a pharmaceutically acceptable carrier.